Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Shares Issued: 2020-2025

Historic Shares Issued for Lyell Immunopharma (LYEL) over the last 3 years, with Sep 2025 value amounting to $49.8 million.

  • Lyell Immunopharma's Shares Issued was N/A to $49.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $51.1 million, marking a year-over-year change of. This contributed to the annual value of $1.2 million for FY2024, which is 34.11% down from last year.
  • Per Lyell Immunopharma's latest filing, its Shares Issued stood at $49.8 million for Q3 2025, which was up 26,973.91% from $184,000 recorded in Q2 2025.
  • Over the past 5 years, Lyell Immunopharma's Shares Issued peaked at $391.8 million during Q2 2021, and registered a low of -$1.1 million during Q3 2021.
  • In the last 3 years, Lyell Immunopharma's Shares Issued had a median value of $707,000 in 2024 and averaged $7.6 million.
  • As far as peak fluctuations go, Lyell Immunopharma's Shares Issued tumbled by 3,128.57% in 2021, and later surged by 583.68% in 2022.
  • Lyell Immunopharma's Shares Issued (Quarterly) stood at -$1.1 million in 2021, then spiked by 583.68% to $325,000 in 2022, then surged by 124.92% to $731,000 in 2023, then slumped by 40.08% to $438,000 in 2024, then tumbled by 73.97% to $49.8 million in 2025.
  • Its Shares Issued stands at $49.8 million for Q3 2025, versus $184,000 for Q2 2025 and $438,000 for Q4 2024.